Autoimmune Liver Disease
7
4
4
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
14.3%
1 terminated out of 7 trials
66.7%
-19.9% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (7)
TruGraf Liver Gene Expression Serial Test
PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
A Study of SIPLIZUMAB in AILD and LT Patients
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Patterns and Outcome of Autoimmune Related Liver Disease
Clinical Observation of Long-term Efficacy and Safety of Glycyrrhizic Acid Preparation in the Therapy of Autoimmune Liver Disease